ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
Bals R: Epithelial antimicrobial peptides in host defense against infection
KosiborodMNVermaSBorlaugBAButlerJDaviesMJJon JensenTet al
A key driver of this process is insulin resistance, which affects both hepatic and peripheral tissues, creating a metabolic environment that simultaneously promotes hyperglycemia and hepatic steatosis through selective pathway activation
no aspiration) CDC (Subcutaneous Injection PDF) Technique diagram and site guidance for subcutaneous injections Additional Research and Background These sources provide related context and are not presented as support for a specific statement above